Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Sleepless nights may signal IBD relapse

NCT ID NCT05835973

First seen Nov 21, 2025 · Last updated Jun 17, 2026 · Updated 26 times

Summary

This study looks at whether changes in sleep can warn of a flare-up in people with inflammatory bowel diseases like Crohn's disease or ulcerative colitis. Researchers will track sleep patterns and disease activity in 216 adults who are currently in remission. The goal is to see if poor sleep happens before a flare, which could help doctors predict and prevent relapses.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHN DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CHU Clermont-Ferrand, Hôpital d'Estaing

    NOT_YET_RECRUITING

    Clermont-Ferrand, 63100, France

    Contact

  • CHU Grenoble Hôpital Michallon-Site Nord

    NOT_YET_RECRUITING

    Grenoble, 38700, France

    Contact

  • CHU Saint Etienne

    NOT_YET_RECRUITING

    Saint-Etienne, 42270, France

    Contact

  • Lyon Sud hospital

    RECRUITING

    Pierre-Bénite, 69310, France

    Contact

Conditions

The condition(s) this trial relates to.

Crohn disease inflammatory bowel disease intestinal disorder Recurrence Sleep Deprivation ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.